Terns Pharmaceuticals Strategy and Business Model

Executive Overview

Terns Pharmaceuticals is a clinical-stage biotechnology company focused on small-molecule medicines, with its 2024 strategy centered on obesity and oncology. As of the company’s FY2023 Form 10-K and 2024 corporate updates, its two most important value drivers were TERN-601, an oral glucagon-like peptide-1 (GLP-1) receptor agonist for obesity, and TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML). That portfolio mix is strategically important: obesity offers a very large market where a convenient oral therapy could broaden use beyond injectables, while CML is a specialist-led hematology market that is far smaller but potentially more practical for a focused commercial build-out. Terns was founded in 2017 and is headquartered in Foster City, California. It operates with one reportable segment and an asset-light model built around internal R&D leadership plus outsourced clinical and manufacturing partners. The company’s earlier liver-disease programs remain part of its development history, but by 2024 investor messaging was clearly more concentrated on obesity and oncology. Because Terns remained a clinical-stage company, it reported no revenue in FY2023.

Terns Pharmaceuticals at a Glance

Logo
Common name	Terns Pharmaceuticals
Full legal name	Terns Pharmaceuticals, Inc.
Headquarters	Foster City, California, United States
Ownership	Public company
Ticker	TERN
Exchange	NASDAQ
Market Cap	#N/A
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2017; Nasdaq IPO in 2021; portfolio broadened from liver disease into obesity and oncology through in-licensed and internally advanced programs by 2023-2024.
Industry or industries	Biotechnology; Pharmaceuticals
Key products or services	Clinical-stage small-molecule drug development, with pipeline programs in obesity, oncology, and liver disease
Geographic footprint	U.S.-based with global clinical-development and outsourced manufacturing relationships
Business segments as officially reported	One operating and reportable segment
Company website	https://www.ternspharma.com/

1. What Is the Strategy of Terns Pharmaceuticals?

1a. What is the winning aspiration of Terns Pharmaceuticals?

Based on Terns’ FY2023 Form 10-K, 2024 investor materials, and 2024 earnings communications, the company’s practical aspiration is to build a differentiated small-molecule biopharmaceutical company by advancing oral therapies in markets where convenience, efficacy, and chronic use can create substantial value. In 2024, that aspiration was most clearly expressed through TERN-601 in obesity and TERN-701 in CML.

Terns has not publicly framed success around a near-term revenue or margin target. Instead, its more immediate definition of winning is clinical and strategic: generate convincing human data, move lead assets into larger value-inflecting studies, preserve financing runway, and create multiple paths to value creation through eventual commercialization, partnering, or both.
1b. Where does Terns Pharmaceuticals play?

Terns does not attempt to compete across the full pharmaceutical landscape. It has chosen to play in selected disease areas where an oral small-molecule product profile could matter. As of mid-2024, those areas were primarily obesity and targeted oncology, with earlier work in liver disease still part of the portfolio.

In market terms, that means Terns is playing in two very different arenas. Obesity is a massive, broad-based chronic-care opportunity with primary care, specialist, payer, and access complexity. CML is a narrower specialist market centered on hematologists and oncologists, molecular monitoring, and line-of-therapy decisions. That selective where-to-play choice shapes nearly every other strategic decision, including capital allocation, trial design, and future commercialization options.
1c. How does Terns Pharmaceuticals plan to win?

Terns appears to plan to win by pursuing differentiated oral small molecules rather than by being the broadest pipeline company. For TERN-601, the goal is to show that an oral GLP-1 receptor agonist can offer a compelling combination of convenience, tolerability, and clinically meaningful weight loss. For TERN-701, the goal is to show that an allosteric BCR-ABL inhibitor can compete effectively in CML, especially where physicians value efficacy, mutation coverage, and tolerability.

Terns’ model also reflects a second strategic choice: stay relatively asset-light and use external innovation, outsourced development, and portfolio focus rather than building heavy fixed infrastructure too early. In other words, it is trying to win with molecule selection, development execution, and disciplined portfolio management more than with commercial scale today.
1d. What capabilities must Terns Pharmaceuticals have in place?

To make that strategy work, Terns needs a specific set of capabilities. The most important are medicinal chemistry and translational science, clinical development in metabolic disease and hematology, regulatory execution, chemistry manufacturing and controls, and strong vendor management across contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs).

It also needs business-development and licensing capability. Terns’ history shows that externally sourced assets have been important to the portfolio, so the ability to evaluate molecules, negotiate rights, and integrate programs into a focused pipeline is part of its strategic machinery.
1e. What management systems does Terns Pharmaceuticals require?

A company like Terns needs milestone-driven portfolio governance, not just scientific ambition. That means formal go/no-go decisions tied to safety, pharmacokinetics, efficacy signals, and cash runway. It also means strong quality and pharmacovigilance systems, board oversight of development risk, and disciplined trial-execution dashboards because timeline slippage can directly affect financing needs.

Because Terns is pre-commercial and outsourcing-intensive, management systems around vendor performance, clinical enrollment, manufacturing readiness, and budget control are especially important. In a company of this size, strategy execution depends less on formal divisional bureaucracy and more on cross-functional asset teams making fast, evidence-based decisions.

2. What Are the Current Strategic Initiatives of Terns Pharmaceuticals?

As reflected in Terns’ 2024 public materials, the company’s agenda was increasingly concentrated on a small number of high-impact initiatives rather than a broad portfolio build-out.

Advance TERN-601 in obesity. After reporting Phase 1 data in 2024, Terns’ most visible strategic initiative was moving TERN-601 toward Phase 2 development in obesity. The company’s public messaging emphasized oral administration and the possibility of a differentiated profile in a market still dominated by injectables and a limited number of advanced oral programs.
Continue the CARDINAL Phase 1 trial for TERN-701 in CML. Terns has been developing TERN-701 as an allosteric BCR-ABL inhibitor, with the aim of building a clinically meaningful position in CML. The immediate initiative is straightforward: generate more safety and activity data, understand where the drug fits by line of therapy, and define its competitive profile relative to established tyrosine kinase inhibitors and newer allosteric approaches.
Focus capital on the most valuable programs. A major strategic initiative, even if less visible than clinical readouts, is capital discipline. Terns’ 2024 communications suggested a portfolio focus around obesity and oncology. That implies a higher bar for spending on earlier or less central assets and a willingness to sequence investment around the most value-creating milestones.
Maintain optionality around the rest of the pipeline. Terns’ earlier liver-disease programs remain relevant as scientific and strategic assets, but they were not the center of 2024 investor messaging. The practical initiative appears to be preserving optionality while letting the lead obesity and oncology programs drive the story.
Preserve financing runway. For a clinical-stage biotech company, liquidity is itself a strategic initiative. Terns’ development plans depend on keeping enough cash to reach important data milestones without being forced into poor financing choices.

3. What Is the Business Model of Terns Pharmaceuticals?

Terns is a pre-commercial clinical-stage biotech. As of FY2023, it had no approved products and no revenue. That means its current business model is not a traditional product-sales model; it is a capital-allocation and value-creation model built around drug discovery, development, and eventual monetization of successful assets.

What customers actually buy: Today, no end customer is buying an approved Terns medicine. Economically, investors are funding the company’s R&D effort, and future value depends on whether Terns can create licensable or approvable assets. If its lead programs succeed, future customers would buy chronic oral therapies for obesity or CML.
Recurring versus one-time economics: If commercialized, both obesity and CML treatments would likely be repeat-driven rather than one-time. Obesity is a chronic therapy market, and CML treatments are also used over extended periods. That makes the future revenue model potentially durable, but only after major clinical and regulatory hurdles are cleared.
How pricing power works: Future pricing power would depend on differentiation. In obesity, pricing will likely be constrained by payer scrutiny, formulary access, and intense competition. In CML, pricing is more specialist and efficacy-driven, but it is still benchmarked against established targeted therapies.
Why the business mix matters: Obesity could create a much larger revenue opportunity but also a much larger commercialization challenge. CML is smaller, but it may be feasible for a company like Terns to address with a focused specialty model. That mix affects whether Terns ultimately self-commercializes, partners, or uses a hybrid model.
What drives margins and cash generation: Right now, gross margin and operating margin are not meaningful in the way they are for a commercial pharmaceutical company because Terns is spending on R&D rather than generating product revenue. Cash generation is negative and driven mainly by R&D expense, clinical-trial timing, manufacturing scale-up, and general corporate overhead. Long term, small-molecule drugs can support attractive gross margins, but commercialization costs would vary sharply by indication.
Revenue model: At present, Terns is best understood as a research-and-development company funded by equity capital and strategic optionality. In the future, revenue could come from product sales, licensing, milestone payments, or co-development partnerships.

4. What Products and/or Services Does Terns Pharmaceuticals Sell?

As of mid-2024, Terns did not sell any approved pharmaceutical products or commercial services. Its “products” were clinical-stage drug candidates.

TERN-601: An oral GLP-1 receptor agonist being developed for obesity. This appears to be one of Terns’ most strategically important assets because it targets a very large market and fits the company’s focus on oral small molecules.
TERN-701: An allosteric BCR-ABL inhibitor in development for CML. This is the company’s lead oncology asset and potentially the most important program for a focused specialty-commercial opportunity.
TERN-501: A thyroid hormone receptor-beta agonist associated with liver disease development work. This program reflects Terns’ earlier metabolic and hepatology focus.
TERN-101: A farnesoid X receptor agonist also tied to liver disease development. Strategically, it appears less central to the current equity story than TERN-601 and TERN-701, but it remains part of the company’s broader portfolio history.

The offerings with the greatest current strategic importance appear to be TERN-601 and TERN-701. The liver programs matter more as optionality than as the core near-term thesis, based on the emphasis of 2024 investor communications.

5. What Are the Key Competitors or Peers of Terns Pharmaceuticals?

Terns competes indirectly as a company for capital and talent, and more directly at the asset level. Its competitive set therefore spans both obesity and CML, plus liver disease if the company continues to advance those programs.

Novo Nordisk — The leading obesity incumbent through semaglutide-based products and oral semaglutide development. Novo sets an efficacy, access, and scale benchmark for any obesity entrant.
Eli Lilly — A major obesity competitor through tirzepatide and oral incretin development, including orforglipron. Lilly is one of the most relevant large-pharma comparators for TERN-601.
Structure Therapeutics — A clinical-stage biotech focused on oral GLP-1 therapy, making it one of the closest small-cap peer comparables to Terns’ obesity strategy.
Pfizer — A large pharmaceutical company that has pursued oral incretin programs. Even where development plans evolve, Pfizer remains a benchmark for competitive intensity in oral obesity therapeutics.
Viking Therapeutics — A biotech peer in obesity and metabolic disease. Its programs are not identical to Terns’, but it is a meaningful market and investor-comparison peer.
Novartis — The most important established CML comparator because of Gleevec, Tasigna, and especially Scemblix (asciminib), which is the closest commercial analogue to TERN-701’s allosteric approach.
Bristol Myers Squibb — A longstanding CML competitor through Sprycel and other hematology presence. It matters as part of the standard-of-care landscape TERN-701 must challenge.
Takeda — Relevant in resistant CML segments through Iclusig. Takeda is part of the later-line competitive environment.
Ascentage Pharma — A more targeted competitor in CML innovation, particularly in resistant disease settings and certain geographies.
Madrigal Pharmaceuticals — If Terns continues to pursue liver disease assets, Madrigal is a relevant peer because it has become a major point of reference in metabolic liver disease.

The most important point is that Terns does not face one single competitive set. Its obesity program competes in a massive and crowded metabolic race, while its CML program competes in a specialist oncology market where differentiation can be clearer but incumbency is strong.

6. What Is the Marketing Strategy of Terns Pharmaceuticals?

Terns is not yet a commercial-stage company, so its current marketing strategy is better understood as scientific positioning rather than brand advertising or large-scale demand generation. The main audiences today are investigators, key opinion leaders, potential partners, regulators, and public-market investors.

Scientific and medical communication: Conference presentations, clinical data releases, and investor presentations are the company’s most important current marketing tools.
Key opinion leader engagement: In obesity and hematology, physician opinion leaders help shape trial design, endpoint relevance, and eventual adoption potential.
Investor relations: For a pre-revenue biotech, capital markets communication is a strategic capability because financing access depends heavily on credibility and clarity.

Marketing does not appear to be a major competitive differentiator today in the way it would be for a consumer-health or established pharma company. If TERN-701 reaches market, Terns could potentially rely on a focused specialist medical and commercial approach. If TERN-601 reaches market, however, the company would face a much larger branding, access, and channel challenge, which could make partnering more attractive.

7. What Are the Key Customer Segments of Terns Pharmaceuticals?

Because Terns is pre-commercial, its customer segmentation is partly prospective. The most useful way to think about it is by future treatment market and current strategic counterparty.

Obesity prescribers and patients: If TERN-601 succeeds, the relevant market includes obesity specialists, endocrinologists, some primary care physicians, patients seeking oral treatment options, and the payers who determine access.
Hematologists and oncologists treating CML: For TERN-701, the key future customer segment is specialist physicians and treatment centers that manage chronic leukemia patients and compare therapies by efficacy, mutation profile, tolerability, and sequencing logic.
Payers and pharmacy-benefit decision makers: Especially in obesity, reimbursement and utilization management could determine commercial success as much as physician interest.
Potential pharmaceutical partners: Even before approval, large biopharma companies can become important “customers” in an economic sense if they license, co-develop, or commercialize assets.

Terns is therefore not dependent on one classic customer group today. Instead, its market structure is split between a future broad metabolic market and a future narrower oncology specialty market.

8. What Is the Sales Model of Terns Pharmaceuticals?

Terns currently has no commercial sales model because it has no approved products. Its go-to-market design is therefore still prospective and likely to differ by asset.

Current state: The company’s present “sales” activity is effectively business development, investor communication, and medical/scientific engagement rather than product selling.
Potential future model for TERN-701: If approved in CML, TERN-701 could fit a focused specialty-sales model calling on hematologists, oncologists, and major treatment centers. That is commercially more manageable for a small biotech.
Potential future model for TERN-601: Obesity would likely require a broader commercialization footprint, stronger payer infrastructure, and potentially much wider physician coverage. That raises the odds of a partnership, co-promotion, or staged commercial build-out rather than a simple solo launch.
Channel implications: The channel structure affects pricing, customer intimacy, and capital needs. A specialty oncology model can support deep physician engagement with a small field force; obesity likely requires broader access capabilities and stronger reimbursement infrastructure.

This channel asymmetry is one of the most important strategic facts about Terns. The same company is developing assets that could require two very different commercial models.

9. In What Geographies Does Terns Pharmaceuticals Operate?

Terns is headquartered in Foster City, California and is managed primarily as a U.S.-based biotech company. Its most visible operating footprint is in the United States, particularly around corporate leadership, clinical strategy, regulatory work, and investor communication.

That said, the company’s effective operating geography is broader than its office footprint. Like many clinical-stage biotech companies, Terns uses global CROs, CDMOs, specialty laboratories, and potentially international trial sites. Its history also includes cross-border licensing relationships, which give the company a more international R&D profile than a purely domestic biotech.

Terns does not appear to have a large owned global infrastructure of plants, warehouses, or country-level commercial subsidiaries. Its geographic model is better described as a U.S.-centered organization with globally distributed development and supply partners.

10. Who Are the Owners of Terns Pharmaceuticals?

Terns Pharmaceuticals is publicly traded and, as of its 2024 proxy-era disclosures, did not appear to have a controlling shareholder. Like many small-cap biotech companies, its ownership base has been led primarily by institutional investors and specialist healthcare funds rather than by a founder with voting control.

Public filings in early 2024 indicated meaningful holdings by healthcare-focused investment firms and venture-origin biotech investors, including historically significant life-sciences backers such as funds affiliated with Vivo Capital and Decheng Capital. Because ownership in development-stage biotech can change quickly, the most current proxy statement and 13G/13D filings are the best source for up-to-date positions.

11. How Is Terns Pharmaceuticals Organized?

Officially, Terns reports one operating and reportable segment. Practically, it appears to be organized as a centralized clinical-stage biotech rather than as a multi-division pharmaceutical company.

That means the company is likely managed through core functions such as research, clinical development, regulatory affairs, medical affairs, technical operations, quality, finance, and corporate development. Individual assets such as TERN-601 and TERN-701 are then managed through cross-functional program teams rather than fully separate business units.

This structure is typical for a company at Terns’ stage. It allows management to shift resources between programs as data emerge, which is more important than maintaining fixed divisional boundaries.

12. How Does Terns Pharmaceuticals Operate?

On a day-to-day basis, Terns operates as a portfolio manager and development engine for drug candidates. Its core activities include candidate optimization, preclinical testing, regulatory planning, clinical-trial execution, manufacturing oversight, safety monitoring, and intellectual-property management.

Terns appears to use an asset-light operating model. Rather than owning large manufacturing plants or running every lab process internally, it relies on outside partners for much of its clinical and production work. That shifts the operating challenge from plant utilization to vendor orchestration and development execution.

The main operating bottlenecks for a company like Terns are usually:

clinical-site activation and patient enrollment,
manufacturing and formulation readiness for clinical supply,
timely generation of safety and pharmacokinetic data,
regulatory interactions and protocol amendments,
and maintaining cash runway while trials are still producing uncertain outcomes.

For Terns, value is created not by high-volume production today but by making good portfolio choices and moving the right molecules through development efficiently.

13. What Are the Growth Opportunities for Terns Pharmaceuticals?

Terns’ growth opportunities are substantial, but they are highly contingent on clinical success.

Oral obesity therapy: The biggest opportunity is clear. If TERN-601 can show a compelling efficacy, tolerability, and convenience profile, Terns would be participating in one of the largest growth markets in biopharma.
CML differentiation: TERN-701 offers a more focused but potentially attractive opportunity if it can show strong utility in a treatment landscape that values molecular response and sequencing flexibility.
Combination potential: Oral small molecules can be attractive building blocks for combination regimens in obesity and metabolic disease. This is a plausible opportunity, although it remains future-oriented rather than proven.
Partnering and licensing: Terns could create value not only through full self-commercialization but also through regional partnerships, co-development deals, or monetization of non-core assets.
Pipeline expansion through business development: The company’s history suggests that external sourcing can be part of its growth model. If management remains disciplined, additional licensed assets could broaden the pipeline without requiring a platform-scale internal discovery engine.

The main constraints are equally clear: clinical failure, financing needs, severe competition in obesity, regulatory risk, and the challenge of proving differentiation against larger and better-capitalized rivals.

14. What Is the History of Terns Pharmaceuticals?

2017: Terns Pharmaceuticals was founded to build a small-molecule biopharmaceutical company targeting serious diseases with high unmet need.
Early years: The company assembled a portfolio with a strong emphasis on metabolic and liver disease, including programs relevant to what is now commonly called metabolic dysfunction-associated steatohepatitis (MASH).
2021: Terns completed its initial public offering and became a Nasdaq-listed company, giving it broader access to public-market capital.
2022-2024: The company broadened its strategic focus through additional pipeline development in obesity and oncology, including TERN-601 and TERN-701.
By 2024: Terns’ public identity had shifted meaningfully. While liver disease remained part of its history and portfolio, investor attention was much more concentrated on oral obesity and targeted hematology.

The most important historical theme is portfolio evolution. Terns did not stay fixed in one disease category; it moved toward areas where management appeared to see stronger risk-adjusted opportunity.

15. What Are the Key Suppliers to Terns Pharmaceuticals?

Suppliers matter a great deal to Terns because it operates with an outsourced development model. The company does not appear to rely on one publicly dominant branded supplier in the way a manufacturer might rely on a single engine or chip vendor, but several supplier categories are strategically important.

Contract research organizations (CROs): These partners support trial execution, site management, data collection, and monitoring.
Contract development and manufacturing organizations (CDMOs): These suppliers help produce active pharmaceutical ingredients, finished dosage forms, and clinical trial material.
Specialty laboratories and central labs: These vendors are important for biomarker work, pharmacokinetics, and molecular response testing.
Formulation, analytical, and quality partners: Oral small-molecule programs still require robust chemistry, manufacturing and controls work, especially as trials scale.
Clinical packaging and logistics providers: These partners matter for shipping drug supply to sites and maintaining trial continuity.

Terns does not broadly disclose a full named vendor list in the way a commercial industrial company might name major suppliers. Strategically, what matters is that supplier execution can directly affect trial timing, cash burn, and regulatory readiness. In an outsourced biotech, supplier reliability is part of the operating model.

16. What Is the R&D Strategy of Terns Pharmaceuticals?

Terns’ R&D strategy appears to focus on orally available small molecules in high-value disease areas, rather than on building the broadest possible platform across many modalities. That matters because it narrows the company’s scientific challenge to a set of capabilities it can realistically support: medicinal chemistry, translational biology, early clinical development, and targeted portfolio expansion.

Three features stand out in Terns’ R&D approach:

Target product profile discipline: The company appears to prioritize molecules where oral dosing could itself be part of the differentiation story.
Early proof-of-concept focus: Terns’ development logic is to generate human data that can clarify whether an asset deserves larger investment.
Blend of internal execution and external sourcing: The portfolio history suggests that licensing and business development are part of how Terns builds its pipeline, not just a secondary activity.

In practical terms, Terns is trying to create value by identifying drug candidates that are good enough to matter clinically and differentiated enough to justify further capital. That is a disciplined R&D strategy for a company of its size, even though it also means the company is highly dependent on a small number of programs.

17. What Is the Finance Strategy of Terns Pharmaceuticals?

Terns’ finance strategy is the finance strategy of a pre-revenue biotech: convert cash into value-creating clinical milestones while preserving enough runway to avoid being forced into weak financing decisions. The company has no dividend or buyback story and no meaningful operating cash generation from product sales. Its key financial questions are liquidity, burn rate, portfolio prioritization, and timing of capital raises.

Several finance principles appear central:

Runway management: Trial design and sequencing must fit available liquidity.
Capital discipline: The company’s 2024 emphasis on lead assets implies a finance strategy aligned with portfolio focus, not portfolio sprawl.
Use of public-market capital: Like many emerging biotech companies, Terns has historically depended on equity financing and cash balances rather than recurring operations.
Optional non-dilutive value creation: Licensing or partnering could reduce funding pressure if the right asset and economics align.

The most important finance insight is that Terns’ capital allocation and its scientific strategy are inseparable. A clinical-stage biotech does not simply finance strategy; its financing capacity is part of the strategy.

18. How Companies Like Terns Pharmaceuticals Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Terns Pharmaceuticals use Umbrex when they need top-tier strategic or operational talent without hiring a full consulting team and all of the associated overhead. For a clinical-stage biotech focused on obesity and oncology, the best uses are usually targeted, high-stakes projects tied directly to pipeline value, partnering choices, development execution, and future commercialization planning.

Obesity target-product-profile benchmarking: Compare TERN-601 against oral and injectable obesity competitors on efficacy, tolerability, access, convenience, and likely commercial positioning.
Partnering strategy for TERN-601: Assess whether Terns should plan for solo commercialization, co-promotion, regional licensing, or a broader strategic partnership if Phase 2 data are strong.
CML market-entry strategy for TERN-701: Build a line-of-therapy opportunity map, competitor response scenarios, and a launch blueprint for a focused hematology market.
Portfolio prioritization and capital allocation: Create a milestone-based framework for deciding how much to invest across TERN-601, TERN-701, and non-core liver assets.
Clinical-operations performance improvement: Review CRO governance, site activation, enrollment bottlenecks, trial dashboards, and vendor-accountability processes.
Chemistry, Manufacturing and Controls (CMC) operating model: Evaluate supplier strategy, manufacturing scale-up risk, formulation readiness, and dual-sourcing options for oral small-molecule programs.
Business-development screening: Identify adjacent assets, combination opportunities, or in-licensing targets in obesity, metabolic disease, or targeted oncology.
Pricing and market-access readiness: Build future payer evidence strategies for obesity and hematology, including reimbursement scenarios and access hurdles.
Pre-commercial organization design: Define what capabilities Terns would need to add if it chose to commercialize TERN-701 itself while potentially partnering a broader obesity launch.
Data and AI enablement for development work: Improve competitive-intelligence workflows, trial analytics, medical-affairs planning, and management reporting without building a large internal transformation team.